Abstract
Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Current Drug Targets
Title:Molecular Pathophysiology of Priapism: Emerging Targets
Volume: 16 Issue: 5
Author(s): Uzoma A. Anele, Belinda F. Morrison and Arthur L. Burnett
Affiliation:
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Abstract: Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Export Options
About this article
Cite this article as:
Anele A. Uzoma, Morrison F. Belinda and Burnett L. Arthur, Molecular Pathophysiology of Priapism: Emerging Targets, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141111111842
DOI https://dx.doi.org/10.2174/1389450115666141111111842 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Chemokines and Receptors as Targets in Anti-Inflammatory Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
Current Hypertension Reviews Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) HIF-1α as a Target for Drug Design in Ischemic Injury: Effect of Cobalt Treatment on Mitochondrial DNA Damage in Cells Exposed to H2O2
Letters in Drug Design & Discovery Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery